To evaluate whether systematic screening for thyroid cancer should be recommended in CHEK2 carriers, a prospective cohort study, comparing the incidence of thyroid cancer in CHEK2 mutation carriers and non-carriers should be set up, preferably including different ethnicities. This evidence concerns the gene CHEK2 and thyroid cancer.